Since targeted therapy, which works by blocking a specific molecular target to inhibit tumor progression and metastasis, is a type of strategy widely used for the treatment of many types of cancer [46], the identification of the right molecular targets, such as p90RSK, on which to act pharmacologically is fundamental to developing successful targeted therapies. This evidence concerns the gene RPS6KA1 and neoplasm.